Kolltan Pharmaceuticals (New Haven, CT) a development-stage biopharmaceutical company focused on monoclonal antibody oncology therapeutics, closed a $8.5M Series B financing. Participants include Celtic Therapeutics Holdings and Tichenor Ventures.

Kolltan Pharmaceuticals (New Haven, CT) an early-stage developer of oncology therapeutics leveraging the receptor tyrosine kinase targets closed a $5M Series A, bring the total financing round to $40M. Participants include Purdue Pharma, HBM Bioventures, the Pritzker family and Diaz and Altschul Capital Management.

Marinus Pharmaceuticals (Branford, CT) a clinical-stage company focused on reformulation and development of therapeutics for the treatment of CNS, psychiatric and pain disorders, closed a $20M Series B financing. Participants include Canaan Partners, Domain Associates, Sofinnova Ventures and Foundation Medical Partners.

Rib-X Pharmaceuticals (New Haven, CT) a clinical-stage small molecule drug discovery company developing antiinfectives against community acquired pneumonia, chronic bronchitis and complicated skin infections, closed a $25M Series D financing. Participants include Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, SR One and Vox Equity Partners.

Kolltan Pharmaceuticals (New Haven, CT) an early-stage developer of oncology therapeutics leveraging the receptor tyrosine kinase targets closed a $35M Series A financing. Participants include Purdue Pharma, HBM Bioventures, the Pritzker family and Diaz and Altschul Capital Management.